Cargando…
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
OBJECTIVE: Identifying molecular changes that contribute to the onset and progression of Huntington's disease (HD) is of importance for the development and evaluation of potential therapies. METHODS: We conducted an unbiased mass‐spectrometry proteomic analysis on the cerebrospinal fluid of 12...
Autores principales: | Niemela, Valter, Landtblom, Anne‐Marie, Nyholm, Dag, Kneider, Maria, Constantinescu, Radu, Paucar, Martin, Svenningsson, Per, Abujrais, Sandy, Burman, Joachim, Shevchenko, Ganna, Bergquist, Jonas, Sundblom, Jimmy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984171/ https://www.ncbi.nlm.nih.gov/pubmed/33247616 http://dx.doi.org/10.1002/mds.28391 |
Ejemplares similares
-
Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington’s disease subjects
por: Herman, Stephanie, et al.
Publicado: (2019) -
Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
por: Niemelä, Valter, et al.
Publicado: (2017) -
Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease
por: Niemelä, Valter, et al.
Publicado: (2018) -
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease
por: Barschke, Peggy, et al.
Publicado: (2022) -
Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas
por: Fazio, Patrik, et al.
Publicado: (2018)